TUĞBA BAŞOĞLU, NAZIM CAN DEMİRCAN, RUKİYE ARIKAN, TUĞBA AKIN TELLİ, SELVER IŞIK, ALPER YAŞAR, ABDUSSAMET ÇELEBİ, ÖZLEM ERCELEP, FAYSAL DANE, PERRAN FULDEN YUMUK
Southern Clinics of Istanbul Eurasia - 2022;33(3):326-330
INTRODUCTION: The aim of this study was to investigate the differences between ampullary carcinomas and pancreatic head carcinomas and to contribute significantly to this issue, which has not been sufficiently addressed in the literature. METHODS: The study was a retrospective descriptive study. The data of 125 patients with resected periampullary adenocarcinoma were retrospectively reviewed between July 2011 and July 2020. The patients were divided into two groups, ampullary and nonampullary carcinomas, and were compared in terms of clinical, demographic, and pathological aspects. Results: A total of 109 patients were included in the study with nonampullary carcinoma predominance (59.6% had nonampullary and 40.4% had ampullary). The most common admission complaint was jaundice. The median follow-up was 24 months (range: 1.480.4 months). Both median overall survival (OS) and median disease-free survival (DFS) were statistically significant longer in ampullary carcinomas compared with nonampullary carcinomas (OS: 74.5 months vs 16.9 months, 95% CI: 12.621.2, p<0.001; DFS: 21.6 months vs 8 months, 95% CI: 10.732.6, p<0.001). DISCUSSION AND CONCLUSION: Ampulla carcinomas are rare tumors with a better prognosis and longer survival than pancreatic head carcinomas. If it is evaluated in a different category from pancreatic tumors, it may be possible to receive less aggressive treatment and avoid unnecessary toxicity for selected patients. Further studies are needed.
